The Protocol Review Committee (PRC) of University of Pittsburgh Cancer Institute (UPCI) is responsible for reviewing all clinical cancer research studies conducted at the University of Pittsburgh and UPMC prior to initiation of the study. Its activities are overseen by the Clinical Research Oversight Committee (CROC) along with two other entities that work in parallel to orchestrate cancer clinical research, the Data Safety and Monitoring Committee (DSMC) and the Clinical Research Services (CRS). The PRC also works in conjunction with three other parts of the clinical trials enterprise, the University of Pittsburgh IRB, the UPCI Biostatistics Facility, and the disease-oriented management teams, to promote the highest scientific quality and most efficient conduct of cancer clinical trials at the UPCI. The PRC is comprised of three committees. Committees A and B each meet once a month in order to facilitate prompt review of cancer treatment protocols. Committee C is responsible for reviewing all behavioral, cancer epidemiology, cancer prevention and control, and complementary medicine protocols as the need arises. The PRC evaluates each protocol to ensure appropriate study design and scientific quality and availability of patient and fiscal resources required for successful completion of the trial proposed. Membership of the PRC includes a diverse group of cancer experts including hematology/oncology, surgical oncology, urologic oncology, pharmacology, biostatistics, nursing, regulatory affairs, and laboratory scientists. PRC approval of cancer clinical trials is required before the study can be submitted to the University of Pittsburgh IRB. All UPCI trials are reviewed for accrual every six months. Studies achieving less than 30% of target accrual are flagged for review. A notification letter is sent to the PI requesting a plan to increase accrual, and the study is re-reviewed for accrual in six months. To simplify documentation and monitoring of UPCI clinical trials activities, all formal committees (PRC, CROC and three DSMC) have a single recording secretary, who is responsible for recording the minutes of each meeting, and facilitates communication between the committees, University and UPMC regulatory committees, regulatory agencies, and UPCI Pis.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2016) Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol :
Concha-Benavente, Fernando; Srivastava, Raghvendra M; Trivedi, Sumita et al. (2016) Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 76:1031-43
Posluszny, Donna M; Dew, Mary Amanda; Beckjord, Ellen et al. (2016) Existential challenges experienced by lymphoma survivors: Results from the 2010 LIVESTRONG Survey. J Health Psychol 21:2357-66
Vyas, Avani R; Moura, Michelle B; Hahm, Eun-Ryeong et al. (2016) Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. J Cell Biochem 117:2482-95
Kirkwood, Caitlin M; MacDonald, Matthew L; Schempf, Tadhg A et al. (2016) Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration. J Neuropathol Exp Neurol 75:175-82
Chen, Mingqing; Sun, Fan; Han, Lei et al. (2016) Kaposi's sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling. Oncotarget 7:33363-73
Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2016) A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res :
Delgado, Evan; Boisen, Michelle M; Laskey, Robin et al. (2016) High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol 141:348-56
Rodler, Eve T; Kurland, Brenda F; Griffin, Melissa et al. (2016) Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res 22:2855-64
Beumer, Jan H; Ding, Fei; Tawbi, Hussein et al. (2016) Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol 34:110-6

Showing the most recent 10 out of 885 publications